The stock of Bioline Rx Ltd ADR (NASDAQ: BLRX) has decreased by -6.53 when compared to last closing price of 5.82. Despite this, the company has experienced a 16.86% gain in its stock price over the last five trading sessions. marketbeat.com reported 2025-06-06 that Markets hate uncertainty, which has been the norm in 2025. Tariffs, interest rates, and inflation are driving analysts’ expectations.
Is It Worth Investing in Bioline Rx Ltd ADR (NASDAQ: BLRX) Right Now?
BLRX has 36-month beta value of 1.30. Analysts have mixed views on the stock, with 1 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for BLRX is 4.07M, and currently, short sellers hold a 4.06% ratio of that float. The average trading volume of BLRX on June 12, 2025 was 649.75K shares.
BLRX’s Market Performance
BLRX stock saw an increase of 16.86% in the past week, with a monthly gain of 76.05% and a quarterly increase of 69.47%. The volatility ratio for the week is 6.59%, and the volatility levels for the last 30 days are 10.54% for Bioline Rx Ltd ADR (BLRX). The simple moving average for the last 20 days is 27.84% for BLRX stock, with a simple moving average of -46.28% for the last 200 days.
Analysts’ Opinion of BLRX
Many brokerage firms have already submitted their reports for BLRX stocks, with Maxim Group repeating the rating for BLRX by listing it as a “Buy.” The predicted price for BLRX in the upcoming period, according to Maxim Group is $3 based on the research report published on May 18, 2017 of the previous year 2017.
Rodman & Renshaw, on the other hand, stated in their research note that they expect to see BLRX reach a price target of $3. The rating they have provided for BLRX stocks is “Buy” according to the report published on February 13th, 2017.
Maxim Group gave a rating of “Hold” to BLRX, setting the target price at $1 in the report published on August 12th of the previous year.
BLRX Trading at 55.49% from the 50-Day Moving Average
After a stumble in the market that brought BLRX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -84.72% of loss for the given period.
#####
#####
Stock Fundamentals for BLRX
Current profitability levels for the company are sitting at:
- -0.71 for the present operating margin
- 0.68 for the gross margin
The net margin for Bioline Rx Ltd ADR stands at -0.32. The total capital return value is set at -0.87. Equity return is now at value -20.03, with -7.15 for asset returns.
Based on Bioline Rx Ltd ADR (BLRX), the company’s capital structure generated 0.53 points at debt to capital in total, while cash flow to debt ratio is standing at -2.92. The debt to equity ratio resting at 1.12. The interest coverage ratio of the stock is -2.25.
Currently, EBITDA for the company is 3.92 million with net debt to EBITDA at 1.18. When we switch over and look at the enterprise to sales, we see a ratio of 0.95. The receivables turnover for the company is 7.49for trailing twelve months and the total asset turnover is 0.74. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.27.
Conclusion
To put it simply, Bioline Rx Ltd ADR (BLRX) has had a mixed performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
